Reestablishment of the Nasal Permeability Barrier to Several Peptides Following Exposure to the Absorption Enhancer Tetradecyl-β-D-Maltoside

被引:15
作者
Arnold, John J. [1 ]
Fyrberg, Michael D. [2 ]
Meezan, Elias [2 ]
Pillion, Dennis J. [2 ]
机构
[1] Samford Univ, McWhorter Sch Pharm, Birmingham, AL 35229 USA
[2] Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA
基金
美国国家卫生研究院;
关键词
insulin; drug delivery; calcitonin; growth hormone; nasal; alkylglycosides; EPITHELIAL-CELLS; DRUG-DELIVERY; INSULIN; BIOAVAILABILITY; CYCLODEXTRIN; CALCITONIN; RABBITS; CAVITY; RATS;
D O I
10.1002/jps.21977
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Regular insulin, NPH insulin, glargine insulin, calcitonin, and human growth hormone were administered to rats nasally with 0.125% tetradecyl-beta-D-maltoside (TDM), or at various times after TDM treatment. Absorption of all five peptides was enhanced initially and diminished in a time-dependent manner as the interval between administration of TDM and the peptide increased. Changes in nasal morphology were also assessed via transmission electron microscopy (TEM) immediately after TDM treatment and at various times thereafter. TEM analysis demonstrated that 0.125% TDM caused a rapid and transient alteration in the morphology of the apical membrane surface. Fewer cilia were observed and cell cell junctions were difficult to visualize, but no epithelial cell erosion was apparent. Two hours after TDM treatment, the apical membrane surface once again contained abundant cilia and cell cell junctions were readily visualized. The complete recovery of the nasal permeability barrier to several different peptides following TDM administration and the concomitant histological evidence demonstrate that TDM treatment transiently perturbs the nasal mucosa to stimulate peptide drug absorption and does not produce irreversible damage to the cells that line the nasal cavity. (C) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:1912-1920, 2010
引用
收藏
页码:1912 / 1920
页数:9
相关论文
共 26 条
[1]   EPITHELIAL TRANSPORT AND BIOAVAILABILITY OF INTRANASALLY ADMINISTERED HUMAN GROWTH-HORMONE FORMULATED WITH THE ABSORPTION ENHANCERS DIDECANOYL-L-ALPHA-PHOSPHATIDYLCHOLINE AND ALPHA-CYCLODEXTRIN IN RABBITS [J].
AGERHOLM, C ;
BASTHOLM, L ;
JOHANSEN, PB ;
NIELSEN, MH ;
ELLING, F .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (12) :1706-1711
[2]   Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-β-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-) [J].
Ahsan, F ;
Arnold, JJ ;
Yang, TZ ;
Meezan, E ;
Schwiebert, EM ;
Pillion, DJ .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 20 (01) :27-34
[3]   Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats [J].
Ahsan, F ;
Arnold, J ;
Meezan, E ;
Pillion, DJ .
PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1742-1746
[4]   Nasal administration of low molecular weight heparin [J].
Arnold, J ;
Ahsan, F ;
Meezan, E ;
Pillion, DJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (07) :1707-1714
[5]   Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells [J].
Arnold, JJ ;
Ahsan, F ;
Meezan, E ;
Pillion, DJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (09) :2205-2213
[6]  
Balzer D., 2000, Nonionic Surfactants: Alkyl Polyglucosides
[7]   Intranasal insulin improves memory in humans: Superiority of insulin aspart [J].
Benedict, Christian ;
Hallschmid, Manfred ;
Schmitz, Katrin ;
Schultes, Bernd ;
Ratter, Frank ;
Fehm, Horst L. ;
Born, Jan ;
Kern, Werner .
NEUROPSYCHOPHARMACOLOGY, 2007, 32 (01) :239-243
[8]   Identification of Tight Junction Modulating Lipids [J].
Chen-Quay, Shu-Chih ;
Eiting, Kristine T. ;
Li, Angela W. -A. ;
Lamharzi, Najib ;
Quay, Steven C. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (02) :606-619
[9]   Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption [J].
Donovan, MD ;
Huang, Y .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (1-2) :147-155
[10]  
EDMAN P, 1992, ADV DRUG DELIVER REV, V8, P165, DOI 10.1016/0169-409X(92)90001-7